ORR by t(11;14) status. (A) Response data for all patients and by t(11;14) translocation status. Patients in the non-t(11;14) group were identified as not having t(11;14) or undetermined cytogenetics. ORR indicates a response of PR or better. (B) Response rates in patient subgroups based on refractoriness to prior therapies among 30 patients with t(11;14) MM. 95% CIs are provided. No patients enrolled in the study had prior exposure to daratumumab. Dotted line indicates an ORR of 40% achieved in patients with t(11;14) MM on this study. CI, confidence interval.